AU2002367266A1 - Disease markers for renal diseaes and utilization thereof - Google Patents
Disease markers for renal diseaes and utilization thereofInfo
- Publication number
- AU2002367266A1 AU2002367266A1 AU2002367266A AU2002367266A AU2002367266A1 AU 2002367266 A1 AU2002367266 A1 AU 2002367266A1 AU 2002367266 A AU2002367266 A AU 2002367266A AU 2002367266 A AU2002367266 A AU 2002367266A AU 2002367266 A1 AU2002367266 A1 AU 2002367266A1
- Authority
- AU
- Australia
- Prior art keywords
- diseaes
- renal
- utilization
- disease markers
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000045500 Diseae Species 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/0108—Ceramide glucosyltransferase (2.4.1.80)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-401076 | 2001-12-28 | ||
JP2001401076 | 2001-12-28 | ||
PCT/JP2002/013777 WO2003057874A1 (en) | 2001-12-28 | 2002-12-27 | Disease markers for renal diseaes and utilization thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002367266A1 true AU2002367266A1 (en) | 2003-07-24 |
Family
ID=19189720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002367266A Abandoned AU2002367266A1 (en) | 2001-12-28 | 2002-12-27 | Disease markers for renal diseaes and utilization thereof |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2003057874A1 (en) |
AU (1) | AU2002367266A1 (en) |
WO (1) | WO2003057874A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070248591A1 (en) * | 2004-09-08 | 2007-10-25 | Takeda Pharmaceutical Company Limited | Preventive/Therapeutic Drug for Arteriosclerosis |
WO2006053043A2 (en) * | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
HUE026057T2 (en) | 2006-05-09 | 2016-05-30 | Genzyme Corp | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
EP2594564B1 (en) | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
KR20150085139A (en) | 2007-10-05 | 2015-07-22 | 젠자임 코포레이션 | Method of treating polycystic kidney diseases with ceramide derivatives |
CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
KR101687039B1 (en) * | 2008-10-03 | 2016-12-15 | 젠자임 코포레이션 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
US10227323B2 (en) | 2013-09-20 | 2019-03-12 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
JP6232689B2 (en) | 2015-06-25 | 2017-11-22 | 株式会社国際電気通信基礎技術研究所 | Prediction device and prediction program based on multi-organ linkage system |
CN114594268A (en) * | 2016-03-29 | 2022-06-07 | 无限生物制药公司 | Screening device and screening method for candidate substance of active ingredient for preventing or treating kidney disease |
CN109414504B (en) | 2016-03-29 | 2022-04-08 | 无限生物制药公司 | Pharmaceutical or food composition and method for evaluating in vivo effect of active ingredient |
JP7109039B2 (en) | 2016-07-07 | 2022-07-29 | 国立大学法人千葉大学 | Antifibrotic agents and phosphorylated Smad nuclear translocation inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2758856B2 (en) * | 1995-06-15 | 1998-05-28 | 理化学研究所 | Ceramide glucosyltransferase |
US6333408B1 (en) * | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
US6277574B1 (en) * | 1999-04-09 | 2001-08-21 | Incyte Genomics, Inc. | Genes associated with diseases of the kidney |
-
2002
- 2002-12-27 WO PCT/JP2002/013777 patent/WO2003057874A1/en active Application Filing
- 2002-12-27 AU AU2002367266A patent/AU2002367266A1/en not_active Abandoned
- 2002-12-27 JP JP2003558172A patent/JPWO2003057874A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JPWO2003057874A1 (en) | 2005-05-19 |
WO2003057874A1 (en) | 2003-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001283163A1 (en) | Automatic transaction management | |
AU2002332079A1 (en) | Clustering | |
AU2001245806A1 (en) | Transactional file system | |
AU4125001A (en) | Computer case | |
AU2001271526A1 (en) | Partner relationship management system | |
AU2002212464A1 (en) | Computer system | |
WO2002031736A8 (en) | Client-driven workflow environment | |
AU2002214471A1 (en) | Map-aided positioning | |
AU2001233626A1 (en) | Marker | |
AUPQ998100A0 (en) | Application development | |
AU2002210726A1 (en) | Software development | |
WO2002080067A1 (en) | Information processor | |
AU2001222135A1 (en) | Information management technique | |
AU2002367266A1 (en) | Disease markers for renal diseaes and utilization thereof | |
AU2001295748A1 (en) | Concurrent file access | |
AU2001288973A1 (en) | Non-genetic based protein disease markers | |
AU2001265071A1 (en) | Clinical trial management | |
AU2001260633A1 (en) | Fas ligand-fused proteins | |
AUPR717701A0 (en) | Management system | |
AU2001296039A1 (en) | Computer | |
AU2001255081A1 (en) | Mouse | |
AU3586501A (en) | Computer network | |
AU2002338094A1 (en) | Bone metablic disease markers and utilization thereof | |
AU2002249582A1 (en) | Disease management system | |
AU2001290112A1 (en) | Computer instructions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |